naftifine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1872 65472-88-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • naftifine
  • naftifine hydrochloride
  • naftifungin
  • naftifine HCl
  • naftifin
allylamine der; RN given refers to unlabeled parent cpd
  • Molecular weight: 287.41
  • Formula: C21H21N
  • CLOGP: 5.52
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -6.10
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 29, 1988 FDA MERZ PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AE22 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Other antifungals for topical use
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
FDA Chemical/Ingredient N0000007522 Allylamine
FDA EPC N0000175874 Allylamine Antifungal

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Tinea corporis indication 84849002
Tinea cruris indication 399029005
Pityriasis versicolor off-label use 56454009 DOID:9060

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.87 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2% NAFTIN SEBELA IRELAND LTD N204286 June 27, 2013 RX GEL TOPICAL 9161914 Jan. 31, 2033 TREATMENT OF FUNGAL INFECTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.06 CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 5.82 CHEMBL
Squalene monooxygenase Enzyme WOMBAT-PK
Squalene epoxidase Enzyme INHIBITOR CHEMBL CHEMBL
C-8 sterol isomerase Enzyme Ki 6.51 CHEMBL

External reference:

IDSource
4019850 VUID
N0000171577 NUI
C0068367 UMLSCUI
D00883 KEGG_DRUG
25UR9N9041 UNII
65473-14-5 SECONDARY_CAS_RN
4588 INN_ID
13800009 SNOMEDCT_US
31476 RXNORM
002929 NDDF
372655002 SNOMEDCT_US
4019850 VANDF
CHEBI:7451 CHEBI
CHEMBL626 ChEMBL_ID
DB00735 DRUGBANK_ID
CHEMBL1200493 ChEMBL_ID
47641 PUBCHEM_CID
C029178 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NAFTIFINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-1510 GEL 10 mg TOPICAL ANDA 10 sections
NAFTIFINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-1512 CREAM 20 mg TOPICAL ANDA 14 sections
Naftin HUMAN PRESCRIPTION DRUG LABEL 1 0259-4126 CREAM 10 mg TOPICAL NDA 11 sections
Naftifine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 40085-203 CREAM 20 mg TOPICAL NDA 15 sections
Naftifine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-1362 CREAM 10 mg TOPICAL ANDA 11 sections
Naftifine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-1368 CREAM 20 mg TOPICAL ANDA 15 sections
Naftifine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-1376 GEL 20 mg TOPICAL ANDA 15 sections
Naftin HUMAN PRESCRIPTION DRUG LABEL 1 54766-102 CREAM 10 mg TOPICAL NDA 15 sections
Naftin HUMAN PRESCRIPTION DRUG LABEL 1 54766-770 GEL 10 mg TOPICAL NDA 11 sections
Naftin HUMAN PRESCRIPTION DRUG LABEL 1 54766-772 GEL 2 g TOPICAL NDA 15 sections
Naftin HUMAN PRESCRIPTION DRUG LABEL 1 54868-2185 GEL 10 mg TOPICAL NDA 11 sections
Naftin HUMAN PRESCRIPTION DRUG LABEL 1 54868-2240 CREAM 10 mg TOPICAL NDA 11 sections